{
  "drug_name": "glimepiride",
  "nbk_id": "NBK554600",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK554600/",
  "scraped_at": "2026-01-11T15:30:07",
  "sections": {
    "indications": "Contraindications for glimepiride include the following patient groups and conditions:\n\nDiabetic ketoacidosis\nType I diabetes mellitus\nHypersensitivity to glimepiride",
    "mechanism": "Glimepiride is an insulin secretagogue and, like other sulfonylureas, is only effective in patients with residual pancreatic beta-cell activity. They act at ATP-dependent potassium channels on the cell membrane of pancreatic beta cells, causing iatrogenic depolarization by preventing potassium from exiting the cell. The depolarization activates voltage-dependent calcium channels on the cell membrane, leading to a rise in intracellular calcium and subsequent exocytosis of insulin into the bloodstream.\n[7]\nInsulin then acts on cell membrane receptors triggering GLUT-4 expression and the movement of glucose into the cell, lowering blood glucose levels. Additionally, research has shown that glimepiride interacts with Epac3, a nucleotide exchanger that mediates the exocytosis of insulin granules.\n[8]\n[9]\n[10]\nGlimepiride's effectiveness was highlighted in a study conducted on healthy volunteers. Results demonstrated a linear relationship between serum glimepiride and insulin release in euglycemic and hyperglycemic conditions.\n[11]",
    "administration": "The standard initial dose of glimepiride is between 1 and 2 mg once daily, taken orally before the patient's first meal. Patients who are prone to hypoglycemia should be started at 1 mg once daily and titrated slowly to an appropriate dose. Following initial therapy, the standard maintenance dosage is at 1 to 4 mg once daily; however, this can be gradually titrated up to 8 mg once daily, depending on the patient's blood glucose and hemoglobin A1c levels. It is important to note that current guidelines do not have a fixed dosage regimen for glimepiride, and the dose requires adjustment according to the patient's blood glucose levels and hemoglobin A1c.\n[1]\n\nWhen used for combination therapy with metformin, the clinician should attempt to identify the minimum effective dose of each drug as the risk of hypoglycemia increases with the use of metformin with glimepiride.\n[1]\nDual therapy of glimepiride with insulin is an option in patients with chronic type 2 diabetes whose initial response to blood glucose-lowering medication has diminished. The fasting glucose level requirement for providing this therapy is greater than 150 mg/dL. In this case, patients should start on glimepiride at 8 mg once daily with subsequent adjustments of insulin administration depending on the patient's blood glucose.",
    "adverse_effects": "Glimepiride, like other sulfonylureas, has multiple adverse effects, the most deadly and notorious being its metabolic effects. As glimepiride increases endogenous insulin secretion, this can lead to hypoglycemia. In patients with long-standing diabetes mellitus, hypoglycemic unawareness can manifest where the autonomic symptoms of hypoglycemia are not experienced by the patient, leading to neuroglycopenia symptoms and potential hypoglycemic coma. This situation is particularly dangerous in drivers or those involved in skilled tasks, especially if other hypoglycemic agents are in concomitant use. Weight gain is another significant side effect of sulfonylureas such as glimepiride, which can interfere with management as weight loss is often a major target in the treatment of diabetes. Other adverse effects include vomiting, abdominal pain, diarrhea, erythema multiforme, and exfoliative dermatitis.\n[1]\n[12]",
    "monitoring": "Monitoring methods for glimepiride include frequent self-glucose monitoring and hemoglobin A1c monitoring every 3 to 6 months. In those with renal pathology, monitoring of glomerular filtration rate may be recommended as glimepiride is primarily excreted via the kidneys.",
    "toxicity": "In cases of overdose of sulfonylureas such as glimepiride, hypoglycemia can occur. It is essential to recognize the signs and symptoms of hypoglycemia, which can fall into the following two categories:\n\nAutonomic symptoms such as tremor, palpitations, nausea, tachycardia, diaphoresis, and anxiety\nNeuroglycopenic symptoms such as confusion, fatigue, headache, drowsiness, coma, and seizures.\n\nRapid recognition and reversal of hypoglycemia are essential in improving prognosis in those that have overdosed on glimepiride.\n[13]\nInitial management is intravenous dextrose; however, this is quickly switched to octreotide (long-acting somatostatin analog) as many patients will have sufficient pancreatic function to stimulate endogenous insulin production in response leading to a cycle of dextrose infusion and rebound hypoglycemia. Additionally, activated charcoal should be given as soon as possible for decontamination. In an emergency or pre-hospital setting, intramuscular injections of glucagon can temporarily increase blood glucose via physiological glycogenolysis and gluconeogenesis. However, as glucagon stimulates insulin release, this is not recommended.\n[14]"
  }
}